The system, which is intended for automated insulin delivery, is said to combine the flexibility of the Tandem t:slim X2 with the strength and precision of the CGM
Dexcom G7 CGM System with Tandem t:slim X2 insulin pump. (Credit: Business Wire/Q4 Inc.)
DexCom said that its Dexcom G7 Continuous Glucose Monitoring (CGM) System is now compatible with Tandem Diabetes Care’s t:slim X2 insulin pump across Europe and in South Africa.
The integrated system, which is intended for automated insulin delivery (AID), is said to combine the flexibility of the Tandem t:slim X2 with the strength and precision of the CGM.
Dexcom G7 with Tandem t:slim X2 pump, which comes with Control-IQ technology, was released in the US a month ago.
Tandem Diabetes Care is collaborating with local distributors in Europe and South Africa to facilitate the launch of the integrated system.
The American medical device maker is also working on the distribution of remote software updates to presently eligible t:slim X2 customers.
According to DexCom, the shipments of new products and changes to the pump software are expected to occur throughout the first three months of 2024, with dates varying per nation.
Dexcom EMEA strategic partners VP Jim Berkebile said: “For over a decade Dexcom has been pioneering industry leading CGM connectivity, meaning we have now safely powered AID systems for more than one million patient years of cumulative use. It’s therefore no wonder that Dexcom is the undisputed leader in CGM connectivity and why our sensors are the clear choice for AID systems.
“Moreover, the clinically meaningful health outcomes that result from using the t:slim X2 insulin pump with Control-IQ technology are proven only when the system is connected to Dexcom CGM.”
The findings from the COMISAIR seven-year follow up CGM study have demonstrated a major and continued reduction of HbA1c.
The use of real-time CGM also reduced the risk of the development or progression of diabetic retinopathy in people with Type 1 diabetes.
In addition, the trial confirmed a substantial reduction in HbA1c when Dexcom CGM is integrated with the t:slim X2 insulin pump.
Tandem Diabetes Care president and CEO John Sheridan said: “We’re actively engaged with our local distributors, supporting their efforts to make this exciting new integration available for new customers and to existing t:slim X2 pump users via remote software updates as quickly as possible.”